ELIXA

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomized, placebo-controlled trial

• Unlike liraglutide (LEADER trial), lixisenatide did not demonstrate a reduction in composite CV outcomes.

• In a follow-up exploratory analysis of the ELIXA study data, lixisenatide reduced the progression of macroalbuminuria and resulted in a lower risk of new-onset macroalbuminuria, after adjusting for baseline risk factors. 

Infographic

Reference

Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869.

>